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Objectives: To determine the effectiveness of live attenuated influenza vaccine (LAIV) in reducing23
amoxicillin prescribing in preschool children in primary care.24
Materials and methods: We used The Health Improvement Network (THIN), a large primary care25
database from the United Kingdom. We included children aged two to four years old at the start of26
either the 2013/14 or the 2014/15 winter season, with at least one amoxicillin prescription between27
September and May, irrespective of LAIV vaccination status. We used the self-controlled case series28
method to estimate influenza vaccine effectiveness (VE).29
Results The total study sample included 33,137 children from 378 general practices during the two30
winter seasons. Of these children, 43.4% with at least one amoxicillin prescription had been31
vaccinated. The rate of amoxicillin prescribing was significantly reduced during periods of influenza32
vaccine immunity. The associated VE for amoxicillin prescribing was 12.8% (95% confidence interval33
(CI) 6.9%, 18.3%) in 2013/14 and 14.5% (9.6%, 19.2%) in 2014/15. Given a VE of 14.5%, we estimated34
that amoxicillin prescribing could have been reduced by 5.6% if LAIV uptake in two to four year old35
children increased to 50% in the 2014/15 winter season.36
Discussion: Influenza vaccination of young children may contribute to a reduction in prescribing of37
amoxicillin, one of the most commonly prescribed antibiotics in primary care. Further studies are38
required to confirm the size of the effect.39
40
Introduction41
Influenza causes a major burden on primary and secondary care services and families every winter in42
temperate countries.1-3 Although influenza rarely results in secondary bacterial infection4 it is linked43
with excess antibiotic prescribing in children.5 The symptoms of influenza are diffuse6 and may be44
difficult to distinguish from bacterial infections,7 particularly in primary care where the majority of45
influenza cases present but diagnostic sampling is not widely available. Overuse of antibiotics is a46
major public health challenge due to increased antibiotic resistance.8 It is therefore of interest to47
determine the role of influenza immunisation programmes in reducing antibiotic prescribing.948
Two clinical trials have examined the effect of influenza vaccination on antibiotic prescribing; one of49
live attenuated influenza vaccine (LAIV) in adults,10 the other of inactivated influenza vaccine (IIV) in50
children aged six months to nine years.11 The size of the effect in the paediatric trial was one less51
antibiotic prescription per child per season. Both these studies are now over 15 years old and52
antibiotic prescribing practices have changed over time.53
A new policy of offering annual vaccination with intranasal LAIV to all children aged two to 16 years54
in the United Kingdom began in September 2013.12 In 2015/16, between 34% and 57% (varying by55
UK country) of preschool children aged two to four years were vaccinated in primary care. 13,1456
Whether LAIV reduces antibiotic prescribing is of interest to clinicians, parents and policy makers57
evaluating the impact of the new influenza vaccination programme. There are no trials of the effect58
of LAIV on antibiotic prescribing in children, and further trials are unethical in the UK due to the59
recommendation to vaccinate all children. Observational studies comparing vaccinated and60
unvaccinated children lead to confounding by indication, since both influenza vaccination and61
complications are more common in children with chronic conditions.14,1562
We evaluate the effectiveness of LAIV in reducing antibiotic prescribing in preschool children in63
primary care in the UK. We focus on prescribing of amoxicillin, indicated for two common64
complications of influenza: community acquired pneumonia and (in some children) acute otitis65
media. We used a large primary care database and applied the self-controlled case series (SCCS)66




All data in this study were anonymised. Data collection has been approved by the South East NHS71
Multicentre Research Ethics Committee. The analyses presented here were approved by the72
Scientific Review Committee of the data providers (QuintilesIMS), study reference number SRC 14–73
004.74
Study design: The Self Controlled Case Series method75
This method was originally developed to examine vaccine safety but has now been applied in a range76
of pharmacoepidemiological studies, including for evaluating the effect of influenza vaccination on77
asthma18,19 and chronic obstructive pulmonary disease (COPD) exacerbations.20 The method includes78
only individuals who have had the outcome of interest (cases), and compares the incidence rate79
within each case of the outcome of interest during a time-limited exposed period (eg. the period of80
vaccine protection) to rates during unexposed, or ‘baseline’ periods. Thus, the question is ‘when’81
rather than ‘who’ experience the events. Since the analyses are conditional on each case, any82
characteristics such as gender or prevalence of chronic conditions which do not vary during the83
study period are inherently controlled for.17 Any time-varying factors, like age or seasonal variation84
need to be adjusted for in the analyses.85
Data source86
We used The Health Improvement Network (THIN) primary care database for this study.21 THIN87
contains anonymised longitudinal data on diagnoses, prescriptions, vaccinations and demographic88
information for around 6% of the UK population. THIN is approximately representative of the89
general UK population in terms of demographic characteristics, and primary care practices90
contributing to THIN are representative of all UK general practices in terms of prescribing and91
consultation rates.22,23 Influenza vaccination uptake rates in THIN, including of LAIV, has been found92
to be similar to uptake figures published by UK public health agencies.24,25 Data are entered by the93
general practitioner (GP, primary care clinician) during patient consultations. Prescriptions are94
recorded in THIN using drug codes which map to the British National Formulary.2695
Study period and population96
We examined LAIV effectiveness during the first two winter seasons of the universal childhood97
influenza vaccination programme: 2013/14 and 2014/15. Separate analyses were carried out for98
each season since the influenza strains contained in the influenza vaccine were well matched to the99
circulating strains in the 2013/14 season but less so in 2014/15.12 Influenza A/H1N1 was the100
dominant strain in 2013/14 and A/H3N2 in 2014/15. Children were eligible to be vaccinated from the101
1st September each year. We defined each season from the first Monday in September until the 18th102
May 2014 and 17th May 2015 (Sunday of week 20) respectively, when active surveillance for103
respiratory infections by UK public health agencies end.27104
Children were considered eligible for inclusion in one or both study cohorts if they were registered105
with a THIN practice on the 1st September 2013 or 2014, met the age criteria for the target group to106
receive LAIV in primary care in that respective season (children aged two to three years inclusive on107
the 31st August 2013 for 2013/14 and children aged two to four years inclusive on the 31st August108
2014 in 2014/15), and had at least one amoxicillin prescription during either of the two study109
periods. That is, children were included in the analysis for 2013/14 if they had at least one110
amoxicillin prescription in 2013/14; and in the analysis for 2014/15 if they had at least one111
amoxicillin prescription in 2014/15.112
Children were followed from the start to the end of the study period or until they deregistered from113
the practice. Infections leading to a prescription of amoxicillin are likely to cluster within families. In114
order to ensure independence of outcomes we randomly selected one child per family (identified via115
the family number in THIN24) in the eligible age range for inclusion in the cohort.24116
We included both vaccinated and unvaccinated cases. Since estimation of the relative risk of117
amoxicillin prescribing is within children only, unvaccinated children do not contribute to the118
estimation of the vaccine effect (only to estimation of the other time varying covariates in the119
model). The vaccinated periods are long in relation to the observation period (see below). It would120
be impossible to distinguish between seasonal variation and vaccine effects during periods when121
almost all cases have been vaccinated (as would happen during early spring). Therefore including122
unexposed (ie. unvaccinated) cases makes it possible to more accurately adjust for seasonal123
effects.17124
Outcome125
The outcome in this study was amoxicillin prescriptions. Amoxicillin is indicated for community126
acquired pneumonia and acute otitis media in children who are systemically unwell, at high risk of127
complications, or with persisting symptoms. Petersen et al28 found that only 50-60% of antibiotic128
prescriptions had an associated indication recorded on the same day. Therefore we considered any129
prescription for amoxicillin irrespective of the indication. A child may receive more than one130
amoxicillin prescription each season. One of the assumptions of the SCCS method is that outcomes131
are independent, conditional on the time-varying covariates.16,17 In order to meet this assumption132
we created prescribing episodes and assumed that all amoxicillin prescriptions in a 30-day period133
were associated with the same infection. Separate prescription episodes were assumed to be134
independent of each other. Only the first prescription in each 30 day period was included.135
Influenza vaccination status136
The exposure variable was receipt of LAIV. We used a code list developed for a previous study to137
identify children who have been vaccinated using LAIV and their date of vaccination each season.24138
Children with severe immunosuppression, asthma, or active wheezing are recommended to receive139
IIV rather than LAIV. Children receiving at least one dose of IIV was excluded from the analyses for a140
particular season. Children who are not in a clinical risk group (94.5% of preschool children 24) are141
recommended to receive one dose of LAIV. We therefore did not have a sufficient number of cases142
to examine the effectiveness of two versus one dose of LAIV. Children who had received two doses143
of vaccine were included in the study, but only the effect of one dose was assessed, that is, we did144
not further split the exposure period into subperiods following the first dose and the second dose.145
LAIV vaccination status was treated as a time-varying covariate. The vaccination exposure periods146
are summarised in Figure S1. There is little evidence regarding how long influenza vaccine immunity147
lasts in children.29-31 We assumed that vaccine-induced immunity lasts for six months in our baseline148
scenario, then varied assumptions about vaccine protection in sensitivity analyses.149
Parents of children who required amoxicillin are likely to delay vaccination until symptoms have150
improved. In order for the SCCS model to be valid, the outcome of interest should not influence the151
exposure (LAIV receipt). Therefore, we included a `pre-vaccination’ period in the analyses, lasting152
from the day of vaccination-14 to the day of vaccination-1. We assumed that vaccine induced153
immunity begins at 14 days after vaccination, in line with previous studies.31-33 We therefore154
excluded a 14-day period after the date of vaccination. Excluding the immediate 14-day post-155
vaccination period also allowed us to take into account that amoxicillin prescription rates are likely156
to remain low immediately after vaccination, since children should be in good health at the time of157
vaccination.158
Seasonality and influenza circulation periods159
A number of different virus infections, including influenza, lead to amoxicillin prescribing in children160
during winter seasons. To allow for underlying seasonality of amoxicillin prescriptions (whatever the161
causative pathogen), we split the follow-up time into weeks of the winter season, and adjusted for162
week as a factor variable in the statistical models. By using this approach, we assumed that the163
underlying seasonality (i.e. timing) of respiratory virus circulation (including influenza) is the same164
among vaccinated and unvaccinated children. In terms of vaccine effects, the SCCS model tests165
whether the relative incidence is lower in vaccinated versus unvaccinated periods, adjusted for166
underlying seasonality of amoxicillin prescribing.167
Since we hypothesised that LAIV would only be effective in preventing amoxicillin prescribing during168
periods when influenza virus was circulating in the community, we further split the follow-up time169
into influenza circulating and non-circulating periods and included this variable as a time varying170
covariate in the SCCS model. In the 2013/14 season, influenza circulated between end of December171
2013 (week 52) and end of March (week 14) according to sentinel swabbing schemes run by Public172
Health England (PHE).34 In 2014/15, influenza circulation was established by week beginning of173
December (week 49) and continued until beginning of April (week 15).27174
Statistical analyses175
Only children who had had at least one amoxicillin prescription were included in the analyses. We176
describe their characteristics in terms of age at cohort inception, sex, influenza vaccination status,177
and whether they were in a clinical risk group due to underlying chronic conditions, and therefore178
considered to be at increased risk of influenza-related complications, in each season. We used a179
code list used by PHE to measure vaccination uptake in primary care to define whether a child was in180
a clinical risk group.35 A child was classified as being in a clinical risk group if they had any code181
recorded up to one year before the start of each winter season.182
We plotted the proportion of cases who had been vaccinated and the number of prescriptions each183
week to assess the overlap in timing between exposure and outcome events. The SCCS models were184
fitted using a conditional Poisson regression model. Vaccine effectiveness (VE) was estimated as185
ܸܧ = 1 − ܴܫ ܴ186
where the IRR is the relative rate ratio of amoxicillin prescribing in vaccinated periods, relative to187
unvaccinated periods, estimated by the fully adjusted SCCS model.188
Statistically significant VE in preventing amoxicillin prescriptions was defined as a Wald test p-189
value<0.05. Separate models were fitted for each of the two seasons. We adjusted for single years of190
age (2, 3, 4 and 5 years) as a categorical variable, active influenza circulation and week number as191
time varying covariates.192
We conducted sensitivity analyses to determine the impact of changing assumptions about the193
effect of age and the duration of vaccination protection on VE estimates:194
1) restricting analyses to period of active influenza circulation only (scenario 1).195
2) increasing the number of age groups to six month age groups rather than single years of age196
(scenario 2)197
3) assuming vaccine protection lasts for nine months (scenario 3). This means that vaccine198
protection extends beyond the end of the study period in this scenario.199
4) splitting the six month vaccinated period into two subperiods from 14 days to less than three200
months and three months to less than six months after vaccination (scenario 4)201
Absolute risk differences cannot be obtained using SCCS. We conducted a simple calculation (not202
allowing for herd immunity) to examine the impact of increasing LAIV uptake in two to four year old203
children in England beyond current levels, given our estimated VE. First, we obtained the current204
number of amoxicillin prescriptions in England by estimating the amoxicillin prescribing rate in two205
to four year old children in English THIN practices between September 2014 and April 2015, and206
applying these rates to mid-year population estimates from the Office for National Statistics.36207
Second, by assuming a constant ratio between VE and uptake, with VE set at the estimated value for208
the 2014/15 season, we calculated the expected number of amoxicillin prescriptions209
(Prescriptionsexp) for a given scenario of vaccination uptake (VUS) as:210
211
ܲ݁ݎ ܿݏ ݅ݎ݌݅ݐ݋݊ ݏ௘௫௣ = ܲ݁ݎ ܿݏ ݅ݎ݌݅ݐ݋݊ ݏை௕௦1 − ܸܧ ൬1 − ܸܷௌܸܧܸܷை௕௦൰212
Where PrescriptionsObs is the observed number of prescriptions in 2014/15, VUObs is observed213
vaccination uptake in England in the 2014/15 season (37.6%37), and VE is the vaccine effectiveness214
estimated from our study for 2014/15 (see Text S1).215
We used Stata 1338 for data management and model fitting and R 3.3.1 for graphical output.216
217
Results218
We identified 90,788 children aged 2 to 3 years in 2013 and 142,273 children aged two to four years219
in 2014 (Figure 1). There were 33,137 children from 378 general practices who had at least one220
amoxicillin prescription during either of the two seasons. Of these children, 14,368 (43.4%) had221
received at least one dose of LAIV in either of the two seasons. Overall, 5,071 children (15.3%)222
contributed person time to both study periods. The characteristics of the children in each cohort are223
shown in Table 1. The vast majority of children in either cohort had only one prescription episode224
each season.225
226
Half of the vaccines had been administered by the beginning of November in both seasons (Figure227
2). Amoxicillin prescriptions displayed several peaks, one in the beginning of December, followed by228
two more peaks in mid-February and mid-March. The amoxicillin prescribing rate was lower in the229
14 days before and the 14 days after vaccination among the vaccinated cases in both seasons (Figure230
S2).231
Influenza vaccination was associated with a significant decrease in amoxicillin prescriptions in both232
winter seasons. LAIV VE in preventing amoxicillin prescriptions was 12.8% in 2013/14 and 14.5% in233
2014/15 (Table 2). Overlapping 95% confidence intervals from the two seasons suggest a similar234
effect size. Including the indicator of influenza circulation had negligible effect on influenza VE235
estimates in either season.236
Subdividing the age groups had negligible effect, whereas restricting the study period to weeks with237
active influenza circulation led to a reduction in the number of cases included in the model and238
greater variability in the VE estimates. When vaccine protection was assumed to be nine instead of239
six months, VE estimates increased in both seasons. When we split the vaccinated period into two240
sub-periods, VE point estimates were similar across the two shorter periods. The CIs for the VE241
estimates from all sensitivity analyses overlapped with those for the baseline scenario for both242
seasons.243
We estimate that 626,932 amoxicillin prescriptions were issued to two to four year old children in244
England between September 2014 and April 2015. Assuming a VE of 14.5%, only 591,868 amoxicillin245
prescriptions would have been prescribed in this season had vaccine uptake been 50% in two to four246
year olds (Figure S3) rather than the observed uptake of 37.6%. This amounts to a decrease of247




We found a 12.8% to 14.5% reduced rate of amoxicillin prescribing during periods of LAIV-induced252
immunity in preschool children. The effectiveness of LAIV in preventing amoxicillin prescribing253
episodes was robust to assumptions about the duration of LAIV protection and age effects.254
The study included over 30,000 children during the first two seasons of the universal paediatric255
influenza vaccination programme in the UK. Only a small proportion of amoxicillin prescriptions are256
likely to be prescribed due to influenza complications, and hence any effect of influenza vaccination257
is likely to be small. Therefore, a large study is required to detect a vaccination effect. The large258
number of cases also allowed us to finely adjust for the seasonal pattern of amoxicillin prescribing259
using week of the winter season.260
We used the SCCS method to estimate relative amoxicillin prescribing rates during vaccinated and261
unvaccinated periods within each child. This is the first time SCCS is used to estimate influenza VE in262
children. Use of the SCCS method means any confounding by indication, which often arises in cohort263
studies of influenza VE,39 is implicitly controlled for.264
We could not examine the effect on prescriptions due to particular symptoms. However, we were265
still able to detect a significantly reduced risk of amoxicillin prescribing during periods of LAIV-266
induced immunity. Since such a small proportion of children received two doses of LAIV, we267
examined effectiveness after only one dose. However, these results are relevant to the vast majority268
of children in the UK who are only recommended to receive one LAIV dose.269
One alternative explanation for our result is that GPs are less likely to prescribe antibiotics to270
children who have been vaccinated, if they consider these children to be at lower risk of influenza271
complications. However, GPs are advised to decide on antibiotic prescribing based only on the272
severity and longevity of symptoms and the presence of chronic conditions, not on whether the273
infection is caused by a particular pathogen.40 We therefore consider it unlikely that decisions274
regarding antibiotic prescriptions are based on a child’s vaccination status.275
Three aspects of our study results were unexpected. First, the effect sizes were similar in the two276
seasons under study, despite varying degrees of vaccine strain. We note that significant VE in277
preventing laboratory confirmed influenza was still reported by PHE in 2014/15.12 Rather than simply278
reducing the incidence of influenza-related complications leading GPs to prescribe amoxicillin, LAIV279
may lead to non-specific protection against respiratory infections. Large, randomised clinical trials of280
LAIV in young children with antibiotic prescribing as an outcome are required to address this281
question.282
Second, when we increased the assumed period of LAIV-induced immunity to nine months, the point283
estimate of LAIV VE increased. If protection persists beyond six months, inclusion of the 6-9 month284
period in the reference category of the base scenario will have caused the effect to be285
underestimated. When the assumed period of LAIV immunity is nine months, the immunity period286
extends to the end of observation and the analysis relies heavily on non-vaccinated cases to287
estimate the weekly seasonal effects. However, there is no reason why seasonal effects should differ288
between vaccinated and unvaccinated cases.289
Third, we hypothesised that VE estimate would be highest during the months immediately following290
vaccination. Amoxicillin prescribing is a non-influenza specific outcome. The seasonal pattern of291
overall amoxicillin prescribing is not in alignment with that of influenza, whereas the seasonal292
pattern of prescribing attributable to influenza should be (with some lag). The burden due to293
influenza cannot be deciphered from the data and no method can disentangle the effect of waning294
vaccine immunity from the effect of other circulating viruses leading to amoxicillin prescriptions.295
Overall, our sensitivity analyses are useful in showing that effects beyond six months are protective,296
indicating that LAIV effectiveness is often long lasting throughout the season.297
Further, we found that restricting the observation period to weeks of active influenza circulation led298
to highly variable estimates of the VE estimates. Restricting the study period leads to a reduction in299
statistical power through three mechanisms. First, it reduces the number of cases included in the300
model, as highlighted in the footnote to Table 2. Second, restricting the study period will in this case301
mean that the ratio of exposed versus unexposed time is even larger, leading to a loss of efficiency.302
Third, restricting the study period will mean some vaccinated cases do not contribute any unexposed303
time to the model, meaning that the vaccine effects are estimated based on an even smaller number304
of children. Hence, restricting the study period led to much more variable estimates of VE and larger305
CIs, particularly for the 2013/14 season when the period of influenza circulation was shorter than in306
2014/15. We note that the CIs for Scenario 1 and the baseline scenario overlap in both seasons. In307
the absence of reliable data on the duration of LAIV-induced immunity among children, the size of308
the effect of LAIV on amoxicillin prescribing should therefore not be overestimated. Ongoing309
monitoring of the effect of LAIV on amoxicillin prescribing in preschool children is required.310
Several other viruses, and in particular respiratory syncytial virus (RSV), is known to cause substantial311
morbidity in young children41 and may lead to amoxicillin prescribing. RSV circulation in the UK peaks312
in early December. Since we adjust for week of the winter season, this should not bias our results, as313
long as the incidence of RSV-related prescribing is the same in vaccinated and unvaccinated children.314
One small study has shown an increase in the risk of non-influenza respiratory viruses following IIV315
receipt,42 but these results have not been replicated for LAIV. The risk of bias caused by differential316
timing of RSV circulation in relation to influenza vaccination is therefore likely to be minimal.317
Our results add to a growing body of evidence showing a reduction in antibiotic prescribing318
associated with influenza vaccination.43 Universal influenza vaccination of children could contribute319
to the effort to decrease antibiotic prescribing in primary care, where three quarters of antibiotics320
are prescribed in the UK.44 Based on a simple calculation, we estimated that up to 5.6% of amoxicillin321
prescriptions could be prevented if LAIV uptake in two to four year old children in England had been322
50% rather than the observed 37.6%. More detailed studies are required to model the potential323
impact of increases in influenza vaccination uptake on antibiotic prescribing.324
We found a significantly reduced risk of amoxicillin prescribing during periods of influenza vaccine325
immunity in preschool children vaccinated with LAIV. Influenza vaccination of children may lead to326
reductions in amoxicillin prescribing, but the effect may be small. Further efforts should be made to327
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Variable n (%) n (%)
Age at start of season (years)
2 8254 (53.1) 8475 (37.4)
3 7289 (46.9) 7842 (34.6)
4 6348 (28)
Sex
Male 8088 (52.0) 11613 (51.2)
Female 7455 (48.0) 11052 (48.8)
Vaccinated during the season
No 9226 (59.4) 13272 (58.6)
Yes – one dose 6162 (39.6) 9281 (41)
Yes – two doses 155 (1.0) 112 (0.5)
Clinical risk group
No 14480 (93.2) 20801 (91.8)
Yes 1063 (6.8) 1864 (8.2)
Number of outcome episodes
during season
1 11648 (74.9) 17473 (77.1)
2 2977 (19.2) 4088 (18)
3 or more 918 (5.9) 1104 (4.9)
Total N 15543 22665
450
451
Table 2 Main model results and sensitivity analyses for influenza vaccine effectiveness (VE) in452
preventing amoxicillin prescriptions, according to season, with 95% confidence intervals (CI)453
Winter season
Analysis scenario 2013/14 2014/15
Main analysis (baseline
scenario)
12.6% (6.7%, 18.2%) 14.5% (9.6%, 19.2%)
Sensitivity analyses
Scenario 1: restricting to
periods of active influenza
circulation*
4.2% (-47.4%, 37.7%) 29.5% (13.9%, 42.3%)
Scenario 2: Six month age
groups
12.5% (6.6%, 18.1%) 14.4% (9.5%, 19.1%)
Scenario 3: vaccine protection
lasts for 9 months
21.2% (14.9%, 27.1%) 19.0% (13.7%, 24.0%)
Scenario 4: two vaccination
sub periods:
14 days - <3 months 13.3% (6.8%, 19.2%) 13.9% (8.6%, 18.8%)
3 - <6 months 11.9% (51%, 18.2%) 15.6% (10.0%, 20.9%)
*Models include 7523 children in 2013/14 and 14616 children in 2014/15454
455
Figures456





Figure 2. Cumulative proportion of cases in each cohort vaccinated and the number of amoxicillin462
prescriptions, by week of the study period†463
464
†The shaded area shows period of active influenza circulation, and *indicates peak week of influenza circulation according465
to Public Health England sentinel swabbing schemes.27,34466
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468
- Supplementary Text S1: Deriving a formula for number of amoxicillin prescriptions given different469
vaccination uptake scenarios470
471
- Supplementary Figure S1. Influenza vaccine periods in the SCCS analyses for vaccinated and472
unvaccinated children473
474
- Supplementary Figure S2. Number of days between vaccination and amoxicillin prescription475
episodes among vaccinated amoxicillin prescription cases (numbers above the plot indicate the476
number of events per day in the specified time period)*477
478
*Note that x-axes for the two seasons are not the same479
480
- Supplementary Figure S3. Expected number of amoxicillin prescriptions in two to four year old481
children between September 2014 and April 2015 under varying scenarios of LAIV uptake.482
483
1Text S1: Deriving a formula for number of amoxicillin prescriptions given different
vaccination uptake scenarios
We derived the formula for estimating the number of doses of amoxicillin prescribed for a given
vaccination uptake scenario by first calculating the number of amoxicillin prescriptions that would be
expected in 2-4 year old children in England between September 2014 and April 2015 if estimated
VE was 0% as
ܲ݁ݎ ܿݏ ݅ݎ݌݅ݐ݋݊ ݏ௏ாబ = ௉௥௘௦௖௥௜௣௧௜௢௡௦ೀ್ೞଵି௏ா Equation 1
where PrescriptionsObs are the observed number of amoxicillin prescriptions between September
2014 and April 2015 in England in 2-4 year old children from THIN and VE is the observed VE from
the SCCS analyses in that season.
Second, we assumed a constant ratio between vaccine effectiveness and uptake, and derived the
expression for the expected number of prescriptions for a given vaccination uptake (VUS) as
ܲ݁ݎ ܿݏ ݅ݎ݌݅ݐ݋݊ ݏ௘௫௣ = ܲ݁ݎ ܿݏ ݅ݎ݌݅ݐ݋݊ ݏ௏ாబቀ1 − ௏௎ೄ௏ா௏௎೚್ೞቁ Equation 2
Where VUObs is the observed LAIV uptake in England in two to four year old children in the 2014/15
influenza season, 37.6%.[1] By replacing the expression for PrescriptionsVE0 in Equation 2 with that
from Equation 1 we arrive at the equation to calculate Prescriptionsexp in the main text.
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